Cannabis Learning EDU
Statistics on Depression:
The most commonly diagnosed form of depression is Major Depressive Disorder. Depression is the leading cause of disability in the United States among people ages 15-44.
There are approximately 25 million Americans who suffer from depression every year.
Over 50 percent of all people who die by suicide suffer from major depression.
More Americans suffer from depression than coronary heart disease, cancer, and HIV/AIDS.
(Source: American Foundation for Suicide Prevention, https://afsp.donordrive.com/index)
A possible role for the endocannabinoid system in the neurobiology of depression
Serra, Gino, et al.
Clinical Practice and Epidemiology in Mental Health. 2007, 3(25) (Full).
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
Ashton, CH., et al.
Journal of Psychopharmacology. 2005, 19(3): 293-300 (Full).
Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens
Robbe, David, et al.
Proceedings of the National Academy of Sciences of the United States of America. 2002 Jun 11, 99(12): 8384-8388 (Full).
Mechanism of Cannabinoid Effects on Long-Term Potentiation and Depression in Hippocampal CA1 Neurons
Misner, Dina L., et al.
The Journal of Neuroscience. 1999 Aug 15, 19(16): 6795-6805 (Full).
Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells
Levenes, Carole, et al.
The Journal of Physiology. 1998 Aug 1, 510: 867-879 (Full).
Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression
Moreira, Fabricio A., et al.
Best Practice & Research Clinical Endocrinology & Metabolism. 2009 Feb, 23(1): 133-144 (abstract).
Cannabinoid receptor 1 (CNR1) gene: Impact on antidepressant treatment response and emotion processing in Major Depression
Domschke, Katarina, et al.
European Neuropsychopharmacology. 2008 Oct, 18(10): 751-759 (abstract).
Enhancement f endocannabinoid signaling and the pharmacotherapy of depression
Mangieri, Regina A., et al.
Pharmacological Research. 2007 Nov, 56(5): 360-366 (abstract).
Role of the endocannabinoid system in depression and suicide
Vinod, K. Yaragudri, et al.
Trends in Pharmacological Sciences. 2006 Oct, 27(10): 539-545 (abstract).
A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
Witkin, Jeffrey M, et al.
Trends in Pharmacological Sciences. 2005 Dec, 26(12): 609-617 (abstract).
Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test
Hill, Matthew N., et al.
European Neuropsychopharmacology. 2005 Dec, 15(6): 593-599 (abstract).
Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?
Hill, M. N., et al.
Behavioral Pharmacology. 2005 Sep, 16(5-6): 333-352 (abstract).